From: Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events
Factor | Division (Unit) | Total | Receiver operating characteristics analysis | ||||
---|---|---|---|---|---|---|---|
N = 139 | Median (Inter-quartile range) | AUC | 95% CI, Lower | 95% CI, Upper | P value | ||
Sex | Male | 73 | 0.999 | ||||
Female | 66 | ||||||
Smoking | Yes | 65 | 0.627 | ||||
Never | 74 | ||||||
2 or 3-Dose Vaccination | Yes | 119 | 0.687 | ||||
No | 20 | ||||||
Age | (Years) | 69.0 (54.0–85.0) | 0.49 | 0.385 | 0.595 | 0.831 | |
Body Mass Index | (kg/m2) | 22.4 (19.9–25.9) | 0.425 | 0.313 | 0.537 | 0.017 | |
Symptomatic | (Day) | 2.0 (1.0–3.0) | 0.399 | 0.301 | 0.497 | 0.022 | |
PreTemp | Celsius | 36.7 (36.2–37.0) | 0.765 | 0.679 | 0.852 | < 0.001 | |
PreOx | (%) | 97.0 (96.0–98.0) | 0.36 | 0.251 | 0.468 | 0.002 | |
While Blood Cell | (× 103) | 5.05 (4.04–6.02) | 0.585 | 0.472 | 0.698 | 0.172 | |
Neutrophil | (%) | 62.6 (53.5–70.7) | 0.693 | 0.594 | 0.791 | 0.007 | |
Lymphocytes | (%) | 23.9 (19.0–32.5) | 0.287 | 0.195 | 0.38 | 0.001 | |
C-reactive protein | (mg/dl) | 1.11 (0.36–2.59) | 0.603 | 0.501 | 0.706 | 0.136 | |
Total Bilirubin | (mg/dl) | 0.50 (0.40–0.70) | 0.532 | 0.426 | 0.638 | 0.699 | |
Creatinine | (mg/dl) | 0.84 (0.68–1.11) | 0.619 | 0.512 | 0.726 | 0.145 | |
Platelet | (× 103) | 182.0 (143.3–224.8) | 0.392 | 0.288 | 0.497 | 0.077 |